Last quarter (Q3 2022), Santen Pharmaceutical Co's total revenue was ¥70.87B, an increase of 5.71% from the same quarter last year. In Q3, Santen Pharmaceutical Co's net income was ¥5.98B. See Santen Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	¥ 206.86B	-	¥ 266.26B	¥ 249.60B	¥ 241.56B	¥ 234.03B
Cost of Revenue	¥ 84.92B	-	¥ 109.67B	¥ 98.22B	¥ 94.83B	¥ 90.76B
Gross Profit	¥ 121.94B	-	¥ 156.59B	¥ 151.38B	¥ 146.72B	¥ 143.26B
Operating Expense	¥ 95.22B	-	¥ 120.70B	¥ 138.47B	¥ 113.19B	¥ 98.16B
Operating Income	¥ 26.71B	-	¥ 35.89B	¥ 12.92B	¥ 33.53B	¥ 45.10B
Net Non Operating Interest Income Expense	¥ 1.42B	-	¥ 1.33B	¥ -142.00M	¥ -1.44B	¥ -1.98B
Other Income Expense	-	-	-	-	-	-
Pretax Income	¥ 26.53B	-	¥ 35.62B	¥ 12.42B	¥ 32.09B	¥ 43.12B
Tax Provision	¥ 6.01B	-	¥ 8.43B	¥ 5.77B	¥ 10.38B	¥ 11.17B
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	¥ 20.56B	-	¥ 27.22B	¥ 6.83B	¥ 23.62B	¥ 31.95B
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	¥ 180.15B	-	¥ 230.37B	¥ 236.69B	¥ 208.02B	¥ 188.93B
Net Income From Continuing And Discontinued Operation	¥ 20.56B	-	¥ 27.22B	¥ 6.83B	¥ 23.62B	¥ 31.95B
Normalized Income	¥ 20.56B	-	¥ 27.22B	¥ 6.83B	¥ 23.62B	¥ 31.95B
Interest Expense	¥ 1.72B	-	¥ 1.21B	¥ 1.49B	¥ 2.39B	¥ 2.88B
EBIT	¥ 28.25B	-	¥ 36.83B	¥ 13.91B	¥ 34.48B	¥ 46.00B
EBITDA	¥ 41.35B	¥ 12.95B	¥ 53.88B	¥ 30.67B	¥ 51.06B	¥ 56.97B

Currency in JPY

Santen Pharmaceutical Co Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing